Targeting TSPAN4 may represent a novel therapeutic strategy for suppressing VSMC-driven vascular remodeling, potentially mitigating clinical conditions such as post-angioplasty restenosis and the progression of atherosclerosis. The gene discussed is TSPAN4; the disease is atherosclerosis.